The treatment options for patients with metastatic clear cell renal cell carcinoma (ccRCC) include anti-angiogenic (AA) therapies (e.g., vascular endothelial growth factor receptor-tyrosine kinase inhibitors VEGF-TKIs), immune checkpoint inhibitors (ICI), mammalian target of rapamycin (mTOR) inhibitors and, most recently, a hypoxia inducible factor (HIF)-2 inhibitor. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.